ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ BẠCH CẦU MẠN DÒNG TỦY BẰNG IMATINIB TẠI BỆNH VIỆN HUYẾT HỌC TRUYỀN MÁU CẦN THƠ

Background: Chronic myeloid leukemia (CML) is a common hematologic malignancy. Previously, treatment mainly focused on controlling leukocytosis and prolonging survival. The advent of targeted therapy has dramatically improved treatment outcomes. Since 2020, when imatinib became covered by health insurance, we have implemented treatment for patients at our hospital.Objective: (1) To describe the clinical and paraclinical characteristics at diagnosis of patients with CML; (2) to evaluate the outcomes of imatinib treatment in CML; (3) to examine the association between EUTOS long-term survival (ELTS) risk groups and the outcomes of imatinib treatment in CML.Subjects and methods: This was a retrospective case series study of CML patients at the Hematology and Blood Transfusion Hospital of Can Tho City from January 2020 to September 2025.Results: The main presenting symptoms were fatigue (64.6%), pallor (57.5%), and splenomegaly (61.4%). The median hemoglobin level was 97 g/L, and the median white blood cell count was 147 G/L. According to the ELTS risk classification, 73.2% of patients were low risk, 18.1% intermediate risk, and 8.7% high risk. Hematologic response rates at 3 and 6 months were 92.9% and 90.1%, respectively. The molecular response rate at 12 months was 87.3% (optimal response 62.0%). The mean overall survival (OS) was 91.7 months, and the mean response survival time was 76.1 months.Conclusion: Treatment of CML with imatinib achieved high response rates and favorable survival.

Authors

Publication Details

Journal
Journal of Clinical Medicine Bach Mai Hospital
Published
2026-11-21
DOI
https://doi.org/10.52322/jocmbmh.156.0307
Primary Topic
Chronic Myeloid Leukemia Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ BẠCH CẦU MẠN DÒNG TỦY BẰNG IMATINIB TẠI BỆNH VIỆN HUYẾT HỌC TRUYỀN MÁU CẦN THƠ

Thien Kim Ly, Minh Phú Huỳnh, Văn Thiếu Phạm, Thị Thu Huyền Lê et al.
Journal of Clinical Medicine Bach Mai Hospital
Chronic Myeloid Leukemia Treatments
article

ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ BẠCH CẦU MẠN DÒNG TỦY BẰNG IMATINIB TẠI BỆNH VIỆN HUYẾT HỌC TRUYỀN MÁU CẦN THƠ

Thien Kim Ly, Minh Phú Huỳnh, Văn Thiếu Phạm, Thị Thu Huyền Lê, Phương Tuấn Đỗ, Ngọc Thùy Dương Trương
article en

Abstract

Background: Chronic myeloid leukemia (CML) is a common hematologic malignancy. Previously, treatment mainly focused on controlling leukocytosis and prolonging survival. The advent of targeted therapy has dramatically improved treatment outcomes. Since 2020, when imatinib became covered by health insurance, we have implemented treatment for patients at our hospital.Objective: (1) To describe the clinical and paraclinical characteristics at diagnosis of patients with CML; (2) to evaluate the outcomes of imatinib treatment in CML; (3) to examine the association between EUTOS long-term survival (ELTS) risk groups and the outcomes of imatinib treatment in CML.Subjects and methods: This was a retrospective case series study of CML patients at the Hematology and Blood Transfusion Hospital of Can Tho City from January 2020 to September 2025.Results: The main presenting symptoms were fatigue (64.6%), pallor (57.5%), and splenomegaly (61.4%). The median hemoglobin level was 97 g/L, and the median white blood cell count was 147 G/L. According to the ELTS risk classification, 73.2% of patients were low risk, 18.1% intermediate risk, and 8.7% high risk. Hematologic response rates at 3 and 6 months were 92.9% and 90.1%, respectively. The molecular response rate at 12 months was 87.3% (optimal response 62.0%). The mean overall survival (OS) was 91.7 months, and the mean response survival time was 76.1 months.Conclusion: Treatment of CML with imatinib achieved high response rates and favorable survival.

Journal of Clinical Medicine Bach Mai HospitalVol. 3(156)
Chronic Myeloid Leukemia Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ BẠCH CẦU MẠN DÒNG TỦY BẰNG IMATINIB TẠI BỆNH VIỆN HUYẾT HỌC TRUYỀN MÁU CẦN THƠ — Thien Kim Ly, Minh Phú Huỳnh, et al. · Journal of Clinical Medicine Bach Mai Hospital (2026) | TGRS Research Map | TGRS